| Zhou, Huan |
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 68 | RoW | T3011 high dose, T3011 middle dose, T3011 low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 12/25 | 05/26 | | |
NCT04808648: The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028 |
|
|
| Not yet recruiting | 1 | 40 | RoW | SH-1028, Itraconazole, Rifampicin | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Healthy Male Volunteers | 06/21 | 06/21 | | |
NCT04951713: Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy Subjects |
|
|
| Recruiting | 1 | 60 | RoW | XZP-3287 combined with clarithromycin, XZP-3287 combined with rifampicin | Xuanzhu Biopharmaceutical Co., Ltd. | Healthy | 09/21 | 12/21 | | |
NCT04689100: Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 259 | RoW | JMT101, FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);, FOLFIRI; mFOLFOX6; Irinotecan; | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumor | 12/21 | 06/22 | | |
| Recruiting | 1 | 189 | RoW | KY-0118 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Neoplasms, Neoplasms by Histologic Type | 12/25 | 12/25 | | |
NCT06232863: A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer |
|
|
| Recruiting | 1 | 24 | RoW | BH009 | Zhuhai Beihai Biotech Co., Ltd | Solid Tumor, Adult | 03/24 | 04/24 | | |
NCT06298071: A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout. |
|
|
| Recruiting | 1 | 36 | RoW | SIBP-R002, Peguricase for injection, Methotrexate | Shanghai Institute Of Biological Products, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Henan University of Science and Technology, Chengdu Fifth People's Hospital | Gout | 12/24 | 12/25 | | |
NCT05302388: A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia |
|
|
| Completed | 1 | 45 | RoW | SIBP-R002, Dexamethasone or Methyl prednisolone, Diphenhydramine, Placebo | Shanghai Institute Of Biological Products, First Affiliated Hospital Bengbu Medical College | Asymptomatic Hyperuricemia | 01/23 | 01/23 | | |
NCT05706207: A Study of HB0030 Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | HB0030 injection, Recombinant Humanized Anti-TIGIT Monoclonal Antibody | Huabo Biopharm Co., Ltd., First Affiliated Hospital Bengbu Medical College | Advanced Solid Tumor | 09/23 | 09/23 | | |
NCT05939596: A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) |
|
|
| Active, not recruiting | 1 | 60 | RoW | SARS-CoV-2 Bivalent mRNA Vaccine, LVRNA021, Saline | AIM Vaccine Co., Ltd., First Affiliated Hospital Bengbu Medical College | SARS-CoV-2 | 09/23 | 08/24 | | |
NCT06144710: SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 48 | RoW | SG301 SC Injection, SG301 SC Placebo | Hangzhou Sumgen Biotech Co., Ltd. | Systemic Lupus Erythematosus (SLE) | 05/25 | 10/25 | | |
NCT06371326: A Study of ZT002 Injection in Participants With Overweight or Obesity |
|
|
| Enrolling by invitation | 1 | 28 | RoW | ZT002 Injection, Placebo | Beijing QL Biopharmaceutical Co.,Ltd | Overweight or Obesity | 08/24 | 09/24 | | |
NCT06360796: Study of Pharmacokinetics and Metabolism on [(14)C]ADC189 |
|
|
| Recruiting | 1 | 6 | RoW | [(14)C]ADC189 | Jiaxing AnDiCon Biotech Co.,Ltd | Pharmacokinetics, Metabolism | 06/24 | 07/24 | | |
GNC-035-103, NCT05160545: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 1 | 29 | RoW | GNC-035 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer | 06/25 | 12/25 | | |
NCT05921006: Ascending Single-Dose and Multiple-Dose Study to Evaluate RJ4287 in Healthy Subjects |
|
|
| Recruiting | 1 | 98 | RoW | RJ4287, Placebo | Nanjing Ruijie Pharma Co., Ltd. | Drug Safety | 12/23 | 12/23 | | |
| Completed | 1 | 24 | RoW | cycle 1: treatment drug, cycle 1: reference drug, cycle 1: fasted, cycle 1: food, cycle 2: treatment drug, cycle 2: reference drug, cycle 2: fasted, cycle 2: food, cycle 3: treatment drug, cycle 3: reference drug, cycle 3: fasted, cycle 3: food | Shenzhen TargetRx, Inc., First Affiliated Hospital Bengbu Medical College | Non Small Cell Lung Cancer | 01/24 | 01/24 | | |
NCT05088070: Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors |
|
|
| Completed | 1 | 40 | NA | SPH 3348 | Shanghai Pharmaceuticals Holding Co., Ltd | Solid Tumor | 07/23 | 07/23 | | |
NCT05684653: Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject |
|
|
| Recruiting | 1 | 34 | RoW | Orelabrutinib Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Hepatic Impairment | 12/23 | 12/23 | | |
NCT05271682: A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma |
|
|
| Recruiting | 1 | 40 | RoW | FHND6091 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Multiple Myeloma | 12/23 | 12/24 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors |
|
|
| Recruiting | 1 | 400 | Europe, US, RoW | KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib | Pierre Fabre Medicament | Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma | 12/24 | 12/25 | | |
NCT05339685: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-M02D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer | 12/24 | 12/24 | | |
NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | SPH5030 tablets | Shanghai Pharmaceuticals Holding Co., Ltd | HER2-positive Advanced Solid Tumors | 12/24 | 12/24 | | |
| Recruiting | 1 | 19 | RoW | TR64 | Tarapeutics Science Inc. | Advanced Solid Tumor | 08/26 | 12/26 | | |
NCT06589635: A Drug-Drug Interaction (DDI) Study of ADC189 With Itraconazole in Healthy, Adult Subjects |
|
|
| Recruiting | 1 | 16 | RoW | ADC-189 and Itraconazole, Part 1: Single dose of ADC-189; Part 2: Itraconazole with single dose of ADC-189 | Jiaxing AnDiCon Biotech Co.,Ltd | Healthy Adults | 09/24 | 12/24 | | |
NCT05673538: TT-00973-MS Tablets in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 40 | RoW | TT-00973-MS tablets treatment | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor | 12/24 | 12/25 | | |
NCT06749236: A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension |
|
|
| Not yet recruiting | 1 | 18 | RoW | test formulation(T) 200 mg deuteriumremidvir hydrobromide for suspension, reference formulation(R) 100 mg deuteriumremidvir hydrobromide for suspension | Vigonvita Life Sciences | Healthy Participants | 03/25 | 03/25 | | |
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 85 | US, RoW | ABSK061 | Abbisko Therapeutics Co, Ltd | Solid Tumor | 04/25 | 04/25 | | |
NCT05574985: Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) |
|
|
| Completed | N/A | 272 | RoW | Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell), Inactivated COVID-19 vaccine (Vero Cell) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., First Affiliated Hospital Bengbu Medical College | COVID-19 | 10/22 | 03/23 | | |
NCT05547256: A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China |
|
|
| Active, not recruiting | N/A | 54 | RoW | COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose, COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose, Placebo | AIM Vaccine Co., Ltd., Ningbo Rongan Biological Pharmaceutical Co. Ltd., First Affiliated Hospital Bengbu Medical College | SARS-CoV-2 | 12/22 | 03/24 | | |
NCT05550142: A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China |
|
|
| Active, not recruiting | N/A | 54 | RoW | SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose, Placebo | AIM Vaccine Co., Ltd., Ningbo Rongan Biological Pharmaceutical Co. Ltd., First Affiliated Hospital Bengbu Medical College | SARS-CoV-2 | 12/22 | 03/24 | | |
NCT05547243: A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China |
|
|
| Active, not recruiting | N/A | 350 | RoW | SARS-CoV-2 mRNA Vaccine, Bivalent Low dose, SARS-CoV-2 mRNA Vaccine, Bivalent High dose, Placebo | AIM Vaccine Co., Ltd., Ningbo Rongan Biological Pharmaceutical Co. Ltd., First Affiliated Hospital Bengbu Medical College | SARS-CoV-2 | 12/22 | 03/24 | | |
NCT05549206: A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People |
|
|
| Not yet recruiting | N/A | 350 | NA | SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose, Placebo | AIM Vaccine Co., Ltd., Ningbo Rongan Biological Pharmaceutical Co. Ltd., First Affiliated Hospital Bengbu Medical College | SARS-CoV-2 | 04/23 | 04/24 | | |
NCT05745545: Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Years and Over |
|
|
| Recruiting | N/A | 3200 | RoW | SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine, Saline solution | AIM Vaccine Co., Ltd., First Affiliated Hospital Bengbu Medical College, Ningbo Rongan Biological Pharmaceutical Co. Ltd. | SARS-CoV-2 | 09/23 | 11/23 | | |
